Ralph DeFronzo
The University of Texas Health Science Center at San Antonio · University of Texas Health San Antonio · University of Texas Health at San Antonio
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ralph DeFronzo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:05 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07925801 · Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol SecretionThe University of Texas Health Science Center at San Antonio · not yet recruiting · Type 2 Diabetes, Hypercortisolism · principal investigator
- Ph3NCT07056699 · SGLT2i, Pioglitazone, and Ketone Production in T1DThe University of Texas Health Science Center at San Antonio · recruiting · Type1diabetes · principal investigator
- Early Ph1NCT07053293 · SGLT2i, Hepatic Glucose Production, and SNSThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- Ph1NCT07053306 · SGLT2i, Ketoacidosis, Volume Contraction, and InsulinopeniaThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- Ph1NCT07053319 · SGLT2i, Pioglitazone, and Ketone Production in T2DThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- Early Ph1NCT06229678 · Ketones, SGLT2, HFrEFThe University of Texas Health Science Center at San Antonio · recruiting · Type2diabetes, Heart Failure With Reduced Ejection Fraction · principal investigator
- Ph1NCT05960656 · SGLTi, Hepatic Glucose Production and KetogenesisThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes · principal investigator
- N/ANCT05867017 · Long-Term Sequelae of SARS-COV-2 Infection: Diabetes MellitusThe University of Texas Health Science Center at San Antonio · completed · COVID-19, Diabete Mellitus · principal investigator
- Early Ph1NCT05093517 · Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DMThe University of Texas Health Science Center at San Antonio · completed · Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity · principal investigator
- N/ANCT04791787 · Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 DiabetesThe University of Texas Health Science Center at San Antonio · completed · Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes · principal investigator
- Early Ph1NCT04300049 · Effect of Physiologic Hyperglucogonemia on Adipocyte MetabolismThe University of Texas Health Science Center at San Antonio · completed · Insulin Sensitivity · principal investigator
- N/ANCT03953963 · Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 DiabetesMedality Medical · unknown · Diabetes Mellitus, Type 2, Insulin Resistance · principal investigator
- Ph4NCT02911792 · Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With HyperfiltrationThe University of Texas Health Science Center at San Antonio · completed · Diabetes Mellitus, Type 2 · principal investigator
- Ph2NCT01819272 · Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 WeeksElcelyx Therapeutics, Inc. · completed · Type 2 Diabetes Mellitus · principal investigator
- N/ANCT01439854 · Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/ActionThe University of Texas Health Science Center at San Antonio · completed · Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome · principal investigator
- Ph4NCT01107717 · Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMThe University of Texas Health Science Center at San Antonio · completed · Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Identification of cell type-specific insulin responsive quantitative trait loci in human skeletal muscleR01DK145103 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2026 · $707,781 awarded in 2026Same name and institution; not confirmed by an ID
- Ketones, Muscle Metabolism, and SGLT2 InhibitorsR01DK107680 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2016 to 2026 · $647,334 awarded in 2026Grant number is on one of their registry trials
- SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 1986 to 2026 · $674,244 awarded in 2026Grant number is on one of their registry trials
- Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizersR01DK129676 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2022 to 2026 · $682,149 awarded in 2026Same name and institution; not confirmed by an ID
- Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican AmericansU01DK085524 · NIDDK · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · fiscal years 2015 to 2019 · $322,775 awarded in 2019Same name and institution; not confirmed by an ID
- Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DMR01DK103841 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2015 to 2017 · $488,805 awarded in 2017Grant number is on one of their registry trials
- SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTIONI01CX001389 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · fiscal years 2016Same name and institution; not confirmed by an ID
- MECHANISM OF INSULIN SENSITIZING EFFECT OF PIOGLITAZONE-ROLE OF ADIPONECTINM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 1990 to 2008 · $2,923 awarded in 2008Same name and institution; not confirmed by an ID
- Regulation of Hepatic and Peripheral Glucose MetabolismR56DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2005 · $73,000 awarded in 2005Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Rachel Sharon Gross, Leora Horwitz, STUART D KATZ, Andrea B Troxel · fiscal years 2021 to 2025Named on NCT05867017
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:05 UTC. The ranking covers the 200 most relevant of 131 PubMed records, and a shared surname and initials can bring in a namesake. All 131 on PubMed
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N Engl J Med · 20061,441 citationsRCR 34.1
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care · 20051,185 citationsRCR 29.3
- Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.N Engl J Med · 19951,013 citationsRCR 28.6
- 892 citationsRCR 32.8
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.J Clin Invest · 2014671 citationsRCR 22.5
- Pioglitazone for diabetes prevention in impaired glucose tolerance.N Engl J Med · 2011565 citationsRCR 15.3
- 384 citationsRCR 8.2
- Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab · 1996375 citationsRCR 9.5
- The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.Diabetes Care · 2009339 citationsRCR 9.6
- Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.Diabetes Care · 2001322 citationsRCR 7.7